Pemetrexed
General properties
Antimetabolites. Structural analogues of folic acid.
Peural malignant mesothelioma
Pemetrexed in combination with cisplatin is indicated for treatment of patients with irresectable peural malignant mesothelioma.
Non-small-cell lung cancer
Pemetrexed in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small-cell non-squamous cell lung cancer.
Pemetrexed as a monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small-cell non-squamous cell lung cancer, whose disease has not progressed immediately following platinum-based chemotherapy.
Pemetrexed as a monotherapy is indicated for the second line treatment of patients with locally advanced or metastatic non-small-cell non-squamous cell lung cancer.
Hypersensitivity to the active ingredient or any excipients of the drug.
Lactation.
Concomitant yellow fever vaccine.
Pediatric use.
Pharmaceutical characteristics
White to almost white powder or mass.
Store in the original packaging at temperature not exceeding 25 0C.
Keep out of reach of children.
